Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 10Myeloproliferative Disorders 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 6Thrombocythemia, Essential 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Neoplasms 4Multiple Myeloma 4Leukemia 4Recurrence 3Polycythemia Vera 3Pancreatic Neoplasms 3Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Myelomonocytic, Chronic 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Colorectal Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Prostatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Syndrome, Transient 1Mycosis Fungoides 1

Interventions

ruxolitinib 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematopoietic and Lymphatic System Neoplasm × ruxolitinib × Clear all
NCT07025538 2026-04-20

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

City of Hope Medical Center

Phase 1 Recruiting
42 enrolled

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡